MedTrace Logo

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

NCT02197806 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2015-12-03

Study results available
· View outcomes & findings →

Summary

A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).

Conditions

Interventions

DRUG

AGN-199201

1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.

DRUG

AGN-190584

1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.

DRUG

AGN-199201 Vehicle

1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-10-31
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02197806 on ClinicalTrials.gov